Boehringer to get Zantac rights as part of J&J-Pfizer deal

10/12/2006 | Yahoo!

Johnson & Johnson and Pfizer say they will sell U.S. marketing rights for the heartburn drug Zantac to Boehringer Ingelheim Pharmaceuticals for $509.5 million as part of J&J's planned acquisition of Pfizer's consumer health business. The sale is intended to facilitate Federal Trade Commission approval of the $16.6 billion J&J-Pfizer deal.

View Full Article in:

Yahoo!

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN